$985.02
4.45[0.45%]
At close: May 24
$985.02
0[0.00%]
After Hours: 4:00PM EDT
Regeneron Pharmaceuticals
(NASDAQ:REGN)Latest News for Regeneron Pharmaceuticals Stock (NASDAQ:REGN)
Regeneron Pharmaceuticals Stock (NASDAQ: REGN)
Categories: All
Friday, May 24, 2024
Monday, May 20, 2024
- (REGN) - Analyzing Regeneron Pharmaceuticals's Short InterestBenzinga Insights - 4 days ago
- Regeneron Pharmaceuticals And Sanofi Present Late-Breaking Data From NOTUS Confirmatory Phase 3 COPD Trial Of Use Of Dupixent; Presented At ATS And Published In New England Journal of MedicineBenzinga Newsdesk - 4 days ago
Friday, May 17, 2024
Tuesday, May 14, 2024
Friday, May 03, 2024
Thursday, May 02, 2024
- Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity InnovationVandana Singh - May 2, 2024, 3:49PM
- Regeneron shares are trading higher, reversing after earlier dropping on a Q1 earnings miss.Benzinga Newsdesk - May 2, 2024, 3:04PM
- Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?Piero Cingari - May 2, 2024, 1:37PM
- Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology IndustryBenzinga Insights - May 2, 2024, 11:00AM
- Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 YearsBenzinga Insights - May 2, 2024, 10:30AM
- Regeneron Pharmaceuticals Q1 2024 Adj EPS $9.55 Misses $10.10 Estimate, Sales $3.145B Miss $3.221B EstimateBenzinga Newsdesk - May 2, 2024, 6:31AM
Tuesday, April 30, 2024
Monday, April 29, 2024
Thursday, April 25, 2024
- AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head StudyVandana Singh - Apr 25, 2024, 1:58PM
- Regeneron, Mammoth Partner To Pursue Next-Generation CRISPR-Based Gene Editing For Multiple Diseases; Mammoth To Receive $100M Total Upfront Payment And Equity InvestmentBenzinga Newsdesk - Apr 25, 2024, 7:28AM
Wednesday, April 24, 2024
- TD Cowen Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030Benzinga Newsdesk - Apr 24, 2024, 1:39PM
- Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCOBenzinga Newsdesk - Apr 24, 2024, 10:06AM
Monday, April 22, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
- Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His PickVandana Singh - Apr 17, 2024, 2:39PM
- If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 TodayBenzinga Insights - Apr 17, 2024, 1:00PM
- Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $925 Price TargetBenzinga Newsdesk - Apr 17, 2024, 9:25AM
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Tuesday, April 09, 2024
Wednesday, April 03, 2024
Monday, April 01, 2024
Thursday, March 28, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
- FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial ConcernsVandana Singh - Mar 25, 2024, 11:50AM
- Regeneron shares are trading lower after the FDA issued Complete Response Letters for the company's Biologics License Application for odronextamab. The company said the only approvability issue is related to the enrollment status of the confirmatory trials.Benzinga Newsdesk - Mar 25, 2024, 7:44AM
- Regeneron Says FDA Issued Complete Response Letters For Biologics License Application For Odronextamab In Relapsed/Refractory (R/R) Follicular Lymphoma And R/R Diffuse Large B-cell LymphomaBenzinga Newsdesk - Mar 25, 2024, 7:02AM